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Adults with Attention Deﬁcit Hyperactivity Disorder (ADHD), especially teenagers and young
adults, show important car driving impairments, including risky driving, accidents, ﬁnes and
suspension of driver's license. We systematically reviewed the efﬁcacy of stimulant and non-
stimulant drugs on driving performance of ADHD patients. We searched several databases for
randomized controlled trials (RCTs) published through March, 2013. Fifteen RCTs (the majority
with crossover design) evaluated methylphenidate (MPH) immediate-release (MPH-IR), MPH
osmotic-controlled oral system (MPH-OROS), MPH transdermal system (MTS), extended-release
mixed amphetamine salts (MAS-XR); atomoxetine (ATX) and lisdexamfetamine (LDX). Methods
varied widely; including simulators and/or cars and different courses and scenarios. Various
outcomes of driving performance, including a ‘composite’ or ‘overall’ driving score were
considered. In general, stimulants improved driving performance in ADHD patients (either in
RCTs conducted in simulators and/or cars). MPH-OROS improved driving performance compared
with MAS-XR, placebo, or no-drug conditions. Although MPH-OROS and MPH-IR produced similar
improvements during the day, MPH-IR lost its efﬁcacy in the evening. MAS-XR also improved
driving performance, but worsened driving performance in the evening. MTS (one study)
showed a positive effect, but drug compliance varied widely across patients. LDX had positive
effect on driving (two studies with the same sample). Studies with ATX report conﬂicting
results. Improvement was more consistent in teenagers and young adults. In general, treatment
with psychostimulants or ATX in therapeutic dosages had no negative impact on drivingo.2014.06.006
CNP. This is an open access article under the CC BY-NC-SA license
/by-nc-sa/3.0/).
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M.A. Gobbo, M.R. Louzã1426performance of ADHD patients. To conclude, treatment with stimulants in therapeutic doses
improves driving performance in ADHD patients, especially teenagers and young adults.
& 2014 Elsevier B.V. and ECNP. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Attention Deﬁcit Hyperactivity Disorder (ADHD) is a common
psychiatric disorder that emerges during childhood and
persists throughout the lifespan (Biederman and Faraone,
2005; Polanczyk and Rohde, 2007) affecting 5.3% of children
and 4.4% of adults worldwide (Polanczyk and Rohde, 2007;
Polanczyk et al., 2007). ADHD is characterized by inatten-
tion, hyperactivity, and impulsivity, which results in several
social and functional impairments (Barkley et al., 1996).
Adults with ADHD exhibit a variety of impairments in their
daily academic, professional, economic, interpersonal, and
affective lives (Barkley et al., 2002; Wilens et al., 2004).
Driving involves multiple complex cognitive functions,
including perception, motor coordination, and executive
function, which are usually impaired in patients with ADHD
(Barkley, 2005, 2006). Therefore, their driving performance
is impaired, which puts themselves as well as the passengers
in their vehicles, other drivers, and pedestrians at risk (Cox
et al., 2011). Several studies have reported that adults with
ADHD are more likely to experience problems associated
with driving, including more ﬁnes, accidents, driving-
related injuries, and the suspension of their driver's license
(Barkley et al., 1996, 2002; Barkley and Cox, 2007; Fischer
et al., 2007). One study has reported that drivers with ADHD
are twice as likely to be involved in motor vehicle accidents
compared with non-ADHD drivers (Ludolph et al., 2009).
A study by Weiss et al. (1979), which followed the course of
ADHD from childhood to adulthood, found that both ado-
lescents and adults with ADHD are more likely to be involved
in motor vehicle accidents than adolescents and adults
without ADHD. Furthermore, Fischer et al. (2007) found
that young adults with ADHD received more ﬁnes for
reckless driving and driving without a license, were involved
in a greater number of minor accidents, had more license
suspensions and revocations, made impulsive driving errors
more frequently and showed less safe driving habits com-
pared with healthy young adults. Laboratory studies using
driving simulators have also reported that individuals with
ADHD are more likely to experience collisions during mono-
tonous driving segments compared with non-ADHD controls
(Biederman et al., 2007). These collisions appear to be
fatigue-related and occur more frequently during the early
morning and late evening (Reimer et al., 2007). Recently,
two studies, one using a driving simulator (Narad et al.,
2013), the other using cars equipped with cameras to
measure driving errors (Merkel et al., 2013), showed that
unmedicated adolescents and young adults with ADHD have
more variability in lane position and speed, more collisions
and more abrupt G-force events (e.g., braking abruptly) in
comparison to non-ADHD controls. Distraction factors, such
as texting in cell phones while driving, impairs even more
the driving performance in the ADHD population (Narad
et al., 2013). Risky behaviors (including Health, Driving andFinancial behaviors) in College students with ADHD were
related to their symptomatology, but Effortful Control
(consisting of activation control, attentional control, and
inhibitory control) and Sensation Seeking were mediators
between symptoms and behaviors, one counterbalancing the
other and inﬂuencing differently the different risk behaviors
(Graziano et al., 2014). For these authors, the risky behaviors
of individuals with ADHD are not related to their symptoms
themselves, but to the ability of the individuals to deal with
their impulsivity in situations with more, or less, immediate
gratiﬁcation, depending on their Sensation Seeking tendencies
and Effortful Control abilities (Graziano et al., 2014).
In a recent meta-analysis, Vaa (2014) estimated the
relative risk (RR) of accidents for drivers with ADHD. The
overall RR for ADHD drivers was 1.36 but decreased to 1.23
when controlling for mileage exposure, as ADHD drivers
drive more than controls without ADHD. The major con-
tributor for the RR=1.23 was the violations of speed. The
RR was not signiﬁcant when property-damage-only acci-
dents were measured (RR=1.07) but was 1.80 (po0.05)
when personal injury is considered. An important confoun-
der is the presence of comorbidities, namely opposite-
deﬁant, personality and conduct disorders: RRs were 1.86
(po0.05) for drivers with these comorbidities and 1.31 (not
signiﬁcant) when no comorbidities were present in the ADHD
sample. The author also calls attention that the studies did not
separate deliberate violations and unintentional driving errors
as the former are linked to accidents, the latter are not.
Psychostimulants are the most common medications that
are prescribed for the treatment of ADHD (Seixas et al.,
2012), and improve symptoms in 60–90% of individuals (MTA
Cooperative Group, 1999; Rappley, 2005; Barry et al., 2009;
Wigal, 2009). Recently, a meta-analysis showed that these
drugs are highly efﬁcacious in the treatment of adult ADHD
with large effect sizes (Faraone and Glatt, 2010). Recent
guidelines have recommended stimulants as the ﬁrst treat-
ment choice for ADHD, with non-stimulants recommended
as a second treatment choice for individuals with comorbid-
ities such as substance abuse, anxiety, or depression
(Pliszka, 2007; Kooij et al., 2010).
In previous reviews of studies on ADHD and driving
performance, Barkley and Cox (2007) and Jerome et al.
(2006) concluded that stimulants may improve the driving
performance of teenagers and adults, and consequently
reduce the risk of citations, license revocations, collisions,
accident-related property damage, and mortality. At that
time, there were only 7 randomized controlled trials that
investigated the effect of medication on driving perfor-
mance of teens and adults with ADHD. Cox et al. (2011)
discussed the ﬁndings of these two old reviews and
suggested that pharmacological and nonpharmacological
approaches may improve driving performance by alleviating
ADHD symptoms, which reduces risks to the patients as well
as their passengers, other drivers, and pedestrians.
1427Inﬂuence of treatment on driving in ADHDThe aim of this study was to conduct a systematic review
of the inﬂuence of stimulant and non-stimulant drug treat-
ment on driving performance in individuals with ADHD.Figure 1 Flow chart detailing results of the process for
identifying relevant literature.2. Experimental procedures
Our systematic review was conducted in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) statement (www.prisma-statement.org/state
ment.htm). An exhaustive search through March 2013 was per
formed using the following databases: PubMed, Lilacs, PsycINFO,
EMBASE, Cochrane, Scielo, and www.clinicaltrials.gov. Initial search
terms that were used without language restrictions were ADHD,
ADD, driving, car, drive, driver, medication, simulator, attention
deﬁcit hyperactivity disorder, and attention deﬁcit disorder.
A second search was performed that included the terms stimulants,
psychostimulants, randomized controlled trials, clinical trials,
methylphenidate, amphetamines, lisdexamfetamine, atomoxetine,
bupropion, and antidepressants.
Studies were included in our review if they were randomized
controlled trials (RCTs) that evaluated the inﬂuence of stimulant or
non-stimulant drugs on driving performance in individuals with
ADHD. Studies were excluded if they were case reports, reviews,
observational trials, case series, studies without drug treatments,
studies that did not use a simulator or a car to evaluate driving
performance, or studies on the inﬂuence of alcohol or other illicit
drugs on driving performance. Studies that met our inclusion and
exclusion criteria were read in full by both authors. Reference lists
were also checked to identify other relevant studies. From the
studies included in our review, relevant information was indepen-
dently extracted by both authors, and a structured evidence table
was organized to synthesize the data. Effect sizes (Cohen's d, unless
otherwise stated) were calculated from the data provided or
reproduced if already determined in the papers.3. Results
We initially found 345 studies using the PubMed, Cochrane,
and EMBASE databases. However, 317 studies were excluded
because, after reading the titles and abstracts, they were
found to be duplicates or were not related to the subject of
this review. The articles for the remaining 28 studies were
read in full, and 14 met our inclusion and exclusion criteria.
One additional study that met our inclusion and exclusion
criteria was found after checking the reference lists of the
14 original studies. Therefore, a total of 15 studies were
included in our review (Figure 1).
The 15 RCTs (see Table 1 for details) included in this
analysis were Cox et al. (2000, 2004a, 2004b, 2006, 2008,
2012); Barkley et al. (2005, 2007),Bjørkli et al. (2005),
Verster et al. (2008), Kay et al. (2009), Mikami et al. (2009),
Biederman et al. (2012a,2012b) and Sobanski et al. (2013).
Although three studies used the same sample, these studies
provided new data on driving performance: Mikami et al.
(2009) and Cox et al. (2008) used the same sample as Cox
et al. (2006) and Biederman et al. (2012b) used the same
sample as Biederman et al. (2012a). All studies were
published in English in the year 2000 or later. Effect sizes
of the main results are included also included in Table 1.
These RCTs included a total of 338 subjects, including 283
ADHD patients, 34 healthy controls, and 21 controls with
ADHD. All ADHD patients were diagnosed according to the
DSM-IV criteria; two studies used the DSM-IV-TR criteria.Twelve RCTs used a crossover design and three RCTs used a
parallel design. Eleven studies were double-blind, three
studies were single-blind, and one study was an open-
label study.
The driving simulation varied among the trials. The
simulation was measured in either distance or time. For
some studies, the driving simulation was conducted at
baseline and after a variable time of treatment. Other
studies were repeated up to 4 times across the day and
night. Different measures of driving performance, such as
the number of collisions, average speed, variation in steer-
ing, brake reaction time, weaving, and sudden decelera-
tions, were quantiﬁed to compare baseline and intervention
conditions; frequently a ‘composite’ or ‘overall’ driving
score was used as primary outcome. When the trial was
performed with a car either a rater (sitting in the car during
the task) used a checklist to obtain the driving parameters
or these were obtained from cameras installed in the car.
Although driving outcomes were the same within studies,
there was a large variation in the driving parameters that
were measured between studies, which made comparisons
across studies difﬁcult. Eight studies evaluated the stimu-
lant methylphenidate (MPH) with different release meth-
ods: MPH immediate-release (MPH-IR), MPH osmotic-
controlled release oral delivery system (MPH-OROS), and
the MPH transdermal system (MTS). Four studies evaluated
extended-release mixed amphetamine salts (MAS-XR), three
studies evaluated the non-stimulant atomoxetine (ATX), and
two studies evaluated the stimulant lisdexamfetamine
(LDX). In three studies, the driving evaluation was con-
ducted approximately 60–90 min after the ingestion of a
single dose of the drug (Cox et al., 2000; Bjørkli et al.,
2005; and Verster et al., 2008); in all other studies, tests
were conducted a variable number of weeks after starting
Table 1 Studies characteristics.
Author,
year
Study design/
blindness
Diagnostic
criteria/
inicial
sample/n1
dropouts
Randomized
sample/gender/
mean age/driving
experience
Drug/dosage Evaluation/method Main results Funding Comments
Cox et al.
(2000)
Counterbalanced
placebo controlled
double blind cross
over study
DSM-IV /13
young adults/
no dropouts
13 Male young
adults/7 with ADHD
and 6 non-ADHD
controls/22.172.3
y.o. (ADHD) and
21.873.0 y.o.
(controls)
MPH-IR vs.
placebo/10 mg
single dosage
Driving simulator/
driving simulation
90 min after drug
ingestion/16-mile
course grade-2 U.S.
highway, duration
of driving
simulation 30 min
MPH-IR better than
placebo (po0.05)
measured with
“impaired
simulator driving
score” for ADHD
patients. Under
MPH-IR ADHD
patients showed
signiﬁcant
improvement in
driving simulation
and self-rating of
driving abilities.
University of
Virginia Health
Science Center
Small sample size,
only males, low
MPH-IR dose, young
drivers (less
experienced),
counterbalanced
design, Probands
received U$100,00.
Cox et al.
(2004a)
Randomized
repeated measures
single blind cross
over study
DSM-IV/12
male teens/no
dropouts
12 Male teens/
17.871.7 y.o./
21715 months of
driving experience
MPH-OROS vs. no
drug/mean dosage
39 mg (0.74 mg/
kg/day). Patients
taking medication
were randomized
to drive on
medication or off
medication on the
day of testing. The
two tests were
separated by one
week.
Own car/16-mile
road course (rural,
highway and
urban), duration
aprox. 45 min/rater
blinded to
medication
condition (on/off)
sat in the back seat
and annotated
impulsive and
inattentive errors
on a standard
checklist
MPH OROS better
than no drug. MPH-
OROS reduced
signiﬁcantly
inattention errors
(po0.01)
(EF=0.85), but not
impulsivity errors
(already low in off-
medication
condition).
Improvement
correlated
positively with
medication dosage.
McNeil Consumer
& Specialty
Pharmaceuticals
Subjects were not
blind to medication
condition (on-off).
Mean MPH-OROS
dosage 0.74 mg/kg.
Small sample, no
placebo. Driving a
car could be more
realistic than a
simulator. Rater
may not be able to
annotate all errors.
A rater on the back
seat might have
hindered impulsive
behaviors.
Subjective
evaluation of errors
by the rater.
Cox et al.
(2004b)
Randomized single
blind cross over
study
DSM-IV/7
male teens/
1 dropout
6 Male teens/
17.271.2 y.o./
15.8712.4 months
MPH-OROS 18 –
144 mg q.d. (8AM)
vs. MPH-IR 30-
Driving simulator/
simulation 4 times/
day at 2 PM, 5PM,
MHP-OROS equal to
MPH-IR during the
day measurements,
McNeil Consumer
& Specialty
Pharmaceuticals
Small sample size,
only males, wide
variation of daily
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of driving
experience
120 mg t.i.d (8AM;
12AM; 4PM)
maintained for
7 days
8PM, 11PM/20-min
driving simulation
but MPH-OROS
better than MPH-IR
in the evening.
Driving
performance
worsened with
MPH-IR but not with
MPH-OROS.
Patients with MPH-
IR had more
inappropriate
breaking (p=0.04)
(EF=1.22), missed
more stop signals
(p=0.02)
(EF=1.38), had a
larger variation of
speed control
(p=0.04)(EF=1.18)
and showed a trend
towards more
collisions (p=0.08)
(EF=1.02).
dosage of MPH,
young drivers (less
experienced),
counterbalanced
design, no placebo
group, dosage of
MPH with high
variability.
Bjørkli
et al.
(2005)
Randomized
placebo controlled
double blind cross
over study
DSM-IV/46
adults/1
dropout
(control)
45 Male adults/17
with adhd and 28
healthy controls/
2877.2 y.o. (ADHD)
3177 y.o.
(controls)
MPH-IR vs.
Placebo/20 mg
single dosage
Driving simulator (5
different segments,
aprox. 9.0 km total
driving simulation);
60 min after drug
ingestion. The
segments are
(1) Highway, low
trafﬁc density,
1 km, 80 km/h;
(2) Highway, long
stretch, slow
moving vehicle
ahead for
overtaking, some
trafﬁc, 2.5 km,
70 km/h;
(3) Highway,
stretch following
intersection, slow
vehicle ahead that
MPH-IR did not
differ from
placebo. A trend
(p=0.06)(EF=0.19)
on the difference in
variance of lateral
position, patients
with placebo had
higher standard
deviation than
patients with MPH-
IR. ADHD group had
a good
performance
already in the
placebo condition,
comparable to
controls. Age
affected the use of
brake pedal (both
mean and variance)
European Union
and Norwegian
Ministry of
Transport and
Communication
Driving tasks not
complicated
enough; ADHD
group may not be
representative of
this population.
Older patients and
controls. Driving
experience not
reported.
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Author,
year
Study design/
blindness
Diagnostic
criteria/
inicial
sample/n1
dropouts
Randomized
sample/gender/
mean age/driving
experience
Drug/dosage Evaluation/method Main results Funding Comments
suddenly stops,
1 km, 50 km/h;
(4) Village drive,
moderate trafﬁc
with other vehicles,
bikes, pedestrians,
4 km, 30-50 km/h
zone: (5) Road
inside the village,
no other trafﬁc,
500 m, 50 km/h
zone.
and mean value of
speed. Patients
with comorbidities
had more variance
in speed and more
steering wheel
movement during
placebo condition.
Barkley
et al.
(2005)
Randomized
placebo controlled
double blind within
subject cross over
study
DSM-IV/56
adults/2
dropouts
40 Males and 14
females/
31.3711.3 y.o./
14.5711.1 years of
driving experience/
2527203 miles
driven per week
MPH-IR 10 mg (low
dose) vs. MPH-IR
20 mg (high dose)
vs. placebo/single
dosage
Driving simulator/
simulation 75 min
after drug intake/
aprox. 15-min
driving simulation/
Patients were
tested in
4 different
conditions
(baseline, 10 mg,
20 mg e placebo)
Signiﬁcant results
(po0.05) in
(1) steering
variability: 20 mg
MPH-IR lower than
placebo (EF=0.42);
(2) number of turn
signals: 10 mg MPH-
IR higher than
placebo (EF=0.20);
(3) average speed:
10 mg MPH-IR
higher than 20 mg
MPH-IR (EF=0.29).
MPH-IR 20 mg
reduced impulsivity
errors on the CPT.
On self-evaluations
of driving abilities,
higher ratings with
MPH-IR in
comparison with
placebo.
National Institute
of Child Health and
Human
Development;
Gerald J. and
Dorothy R.
Friedman
Foundation for
Medical Research
and the Frank and
Nancy Parsons
Foundation
Although signiﬁcant
results, no clear
differences
between 10 and
20 mg MPH-IR,
possible learning
effect, 5% did not
complete simulator
course due to
simulator sickness,
36-39% rated
themselves with
mild or greater
sickness across drug
conditions. 87% of
the sample were
from the combined
subtype; adult
patients with many
years of driving
experience. Sample
with more males.
Patients received
U$150,00
M
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Cox et al.
(2006)
Randomized
placebo controlled
double blind
counterbalanced
cross over study
DSM-IV/35
teens/no
dropouts
35 Teens/19 males
and 16 females/
17.871.7 y.o./
2175 months of
driving experience
MPH-OROS (72 mg)
vs. MAS-XR (30 mg)
vs. placebo taken
at 8AM during at
least 10 days
Driving simulator/
simulations at 5PM,
8PM and 11PM,
15-min driving
simulation each
time
MPH-OROS
improved driving
performance
compared with
placebo (EF=0.82)
and MAS-XR
(EF=0.53); MAS-XR
was comparable to
placebo (EF=0.28).
Better steering,
better speed
control, less
impulsive driving.
McNeil Pediatrics,
Division of McNeil-
PPC Inc.
Small sample size,
possibly
underpowered to
detect differences
between placebo
and MAS-XR.
Medication doses
possibly not
equivalent for
comparison. More
consistent response
(less variability) to
MPH-OROS than to
MAS-XR among
patients. Fixed
doses not adjusted
for each patient.
No washout
between the two
phases of the trial.
Few participants
from the
hyperactive
subtype. Short
duration of the
driving test
(15 min).
Barkley
et al.
(2007)
Within subjects
reversal design,
randomized
placebo controlled
double blind
counterbalanced
order
DSM-IV/32
recruited/14
dropouts
18 Adults/08 males
and 10 females/
36.1712.2 y.o./
19.3711.5 years of
driving experience/
229.27172.8 miles
driven per week
(range: 30–600)
ATX vs. placebo
1.2 mg/kg/day
Driving simulator/
Three driving
evaluations: at
baseline, after
4 weeks of drug/
placebo and after
4 weeks of drug/
placebo; 12-min
driving simulation
Placebo and ATX
better than
baseline; ATX equal
to placebo (driving
time EF=0.16;
total crashes
EF=0.21; mean
brake reaction time
EF=0.01).
Improvement for
total collisions and
mean reaction time
between the
baseline and
placebo condition.
For de crash and
reaction time
scores, signiﬁcant
Partially funded by
a grant from the Eli
Lilly Company to
the Medical
University of South
Carolina
(investigator-
initiated research).
Gerald J. and
Dorothy R.
Friedman
Foundation for
Medical Research;
Frank and Nancy
Parsons Foundation
and National
Institute of Child
Pilot study, small
sample, no washout
for crossover,
possible practice
effect on simulator,
only 12 min on
driving simulation,
72% of the
combined subtype.
No hyperactive
subtype. Patients
received US$150,00
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Author,
year
Study design/
blindness
Diagnostic
criteria/
inicial
sample/n1
dropouts
Randomized
sample/gender/
mean age/driving
experience
Drug/dosage Evaluation/method Main results Funding Comments
improvement
occured between
baseline and ATX
condition but not
between ATX and
Placebo.
Improvement of
symptoms and self-
rating of driving
performance.
Health and Human
Development,
Cox et al.
(2008)
Randomized
placebo controled
double blind
counterbalanced
cross over study
using a subsample
(only male
patients) of the
study by Cox et al.,
(2006)
Same as Cox
et al. (2006)
19 Males/mean
age: 17.4 y.o.
(range: 16–19 y.o.)/
14.4 months
(mean) of driving
experience/
average of 7531
miles driven per
year
Same as Cox et al.
(2006)
Simulator as in Cox
et al. (2006) and a
16-mile on-road
drive (rural,
highway and urban
courses, with rater
at the back seat of
subject’s car) at 12
PM (duration: about
25 min) and driving
simulator at 1 AM
Non signiﬁcant
decay in simulator
performance with
MAS-XR in
comparison to
placebo at 1AM,
compared to 11PM.
On the on-road task
more inattentive
errors with MAS-XR
than with placebo
(po0.04)(EF=0.42)
and MPH-OROS
(po0.008)
(EF=0.90). More
variability (larger
standard deviation)
of on-road and
simulator
measurements in
patients with MAS-
XR compared to
placebo and to
MPH-OROS
McNeil Pediatrics,
Division of McNeil-
PPC Inc.
Possible rebound
effect with MAS-
XR. Small sample
size. No patients
with hyperactivity
subtype of ADHD
M
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Verster
et al.,
(2008)
Randomized
placebo controlled
double blind two-
way
counterbalanced
cross over study
DSM-IV/19
adults/1
dropout
18 Adults/11 males
and 7 females/
38.377.7 y.o./16.8
(range: 3–30) years
of driving
experience/driving
distance: 22,500
(range: 2000–
900,00) km/year
MPH-IR vs. placebo
(dosage according
to patient’s regular
dosage) mean:
14.7 mg (range: 10–
30 mg). Driving test
(100 km on a
highway with
normal trafﬁc),
90 min after
medication
ingestion. Three
days of washout
before the ﬁrst
driving test, then
six to seven days
washout for the
second driving test.
Test car with
camera that
measured lateral
position relative to
road delineation
and speed
(recorded
continuously).
Driving on a
highway during
normal trafﬁc for
100 km at a
constant speed of
95 km/h. Licensed
driving instructor
with access to dual
controls sat in the
right front seat, for
subject’s safety.
MPH IR better than
placebo on the
mean of the
standard deviation
of the lateral
position (weaving)
(21.1 cm vs.
18.8 cm, po0.004;
mean difference:
2.3 cm) (EF=0.61).
No differences in
mean lateral
position, mean and
standard deviation
of speed.
Utrecht University Statistically
signiﬁcant weaving
difference
(2.3 cm). Seven
days washout
between the two
phases of the
crossover. Adult
patients; Wide
differences on
years of driving
experience and
number of km
droven in one year.
No reference to
subtypes. Sample
without
comorbities.
Kay et al.
(2009)
Randomized
placebo-controlled
double blind
crossover studies
(two independent
cohorts). Cohort 1:
MAS XR; Cohort 2:
ATX)
DSM-IV-TR/
Cohort 1: 19
adults/4
dropouts.
Cohort 2: 16
adults/no
dropouts
Cohort 1
(randomized): 19
Adults /17 males
and 2 females/
22,372.1 y.o.,
ﬁfteen subjects
included in ITT
analysis. Cohort 2
(ITT): 16 adults/14
males and
2 females/
22.471.8 y.o.
Cohor1: MAS-XR
dose titration
schedule up to
50 mg/day vs.
placebo. Cohort 2:
ATX dose titration
schedule up to
80 mg/day vs.
placebo. Both
treatments for
3 weeks each (total
6 weeks). No
washout between
the two phases of
the study
Driving simulator (3
different scenarios,
similar difﬁculties).
Three evaluations
in each session (2,
7 and 12 h after
drug
administration).
One hour driving
simulation each
session.
Cohort 1: MAS-XR
better than placebo
at all time points
(mean z-score
difference 0.59;
mean p=0.014).
Cohort 2: ATX did
not differ from
placebo at all time
points (mean
z-score difference
0.04; mean
p=0.293). Cohort
1: improvement
was observed in
number of
collisions, out-of-
lane incidents,
tailgating, time to
collision and
response to crash-
likely events.
Shire
Pharmaceutical
Inc.
Small sample sizes;
no reference to
subtypes of ADHD.
Improvement in
driving
performance
correlated to
improvement in
ADHD symptoms.
Cohorts with only
2 females. No
information about
driving experience.
Patients that had
their drivers’
license suspended
were excluded.
Participants
received U$150,00.
Different software
versions to reduce
the inﬂuence of
practice effects.
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Table 1 (continued )
Author,
year
Study design/
blindness
Diagnostic
criteria/
inicial
sample/n1
dropouts
Randomized
sample/gender/
mean age/driving
experience
Drug/dosage Evaluation/method Main results Funding Comments
Mikami
et al.
(2009)
Randomized
placebo controled
double blind
counterbalanced
cross over study
(same sample of
the study by Cox
et al., 2006).
Objective: to
compare male to
female patients
Same as Cox
et al., (2006)
Same as Cox et al.,
(2006)
Same as Cox et al.,
(2006)
Same as Cox et al.,
(2006), including
neuropsychological
test (computerized
Go/NoGo test and
Delayed-Matching-
to-Sample task) and
rating scales
Male and female
patients have
similar response to
long acting
stimulants in
driving
performance (EF
partial η2=0.01),
neuropsychological
tasks (EF partial
η2=0.44) and
rating scales (EF
partial η2 between
0.00 and 0.05).
McNeil Pediatrics,
Division of McNeil-
PPC Inc.
No registration or
measurement of
females’ menstrual
cycles and
hormonal
variations.
Biederman
et al.
(2012a)
Randomized
placebo controlled
double blind
parallel-design
study
DSM-IV/69
adults
(randomized)/
8 dropouts
61 Adults/38 males
and 23 females/
21.672.1 y.o.
(range: 18–26 y.o.)
Lisdexamfetamine
(LDX) 30–70 mg/day
(weekly titration
from 30 to 70 mg/
day, then, if side
effects, daily
dosage could be
reduced) vs.
placebo. Duration
of the trial:
6 weeks
Driving simulator/
basic scenario and
task presentation
identical.
Simulations
included a period
of moderately
dense urban
driving, then a
straight
unpopulated road
(monotonous)
period, a period of
low density rural
and highway driving
(moderate
demand), and a
straight
unpopulated road
(monotonous).
Baseline session
and second session
In highway, trend
(po0.10) to better
speed control and
less excessive
speeding for LXD
group. Trend
toward reduced
lateral variation
during monotonous
periods for LXD
group. Signiﬁcant
reduction of the
average of reaction
time (p=0.026)
(EF=0.59) to the
ﬁve surprise events
(2nd. simulator
session) for LXD
group. Signiﬁcant
(p=0.048)
(EF=0.52) less
collisions during
Shire
Pharmaceutical
Inc.
No information on
ADHD subtypes;
Differences
between male and
female patients not
reported. Final
mean LDX dosage
not reported. Years
of driving
experience not
reported. Patients
whose drivers
license was
suspended were
not included. Two
dropouts because
of simulator
sickness. Speciﬁc
informations on
adverse events.
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6 wks after
baseline. In the
second session,
addiction of ﬁve
surprise events on
simulation. 43-mile
driving simulation
each session.
the ﬁve surprise
events for LXD
group versus
placebo (7 vs. 14
drivers).
Biederman
et al.
(2012b)
Same as Biederman
et al. (2012a)
Same as
Biederman
et al. (2012a)
Same as Biederman
et al. (2012a)
Same as Biederman
et al. (2012a)
At baseline and
after 6 weeks of
the trial, patients
(LDX group n=29;
placebo group
n=27) fulﬁlled the
self-report
Manchester Driving
Behavior
Questionnaire
(DBQ). Three
subscores (errors,
lapses and
violations) and
total DBQ were
analyzed
At baseline, no
differences
between groups.
After six weeks,
patients on LDX
improved in errors
(po0.02; EF=0.72)
and lapses
subscales (po0.02;
EF=0.71) and DBQ
total score
(po0.01;
EF=0.78). DBQ
scores on LDX
responders and
nonresponders
showed no
signiﬁcant
differences.
Correlations
between DBQ
improvement (total
or subscale scores)
and reaction time
to surprise events
or collisions
(driving simulator)
were not
signiﬁcant.
Shire
Pharmaceutical
Inc.
Same as Biederman
et al., (2012a).
Subjective
evaluation of
driving behavior
may not be a good
proxy for objective
driving behavior
(driving
simulation).
Cox et al.
(2012)
Randomized open-
label crossover
study
DSM-IV TR/25
adults/8
dropouts
17 Adults /14 males
and 3 females/
20.872.4 y.o./
3.871.2 years of
driving experience/
mean distance
MPH transdermal
system (MTS)
(10–30 mg/d
patches) vs. no-
drug. Compliance
Own cars/in-car
video system
(2 cameras)
installed in
rearview mirror
during 3 months
No collisions during
MTS vs. 8 collisions
when off-drug
(z=2.83;
po0.005). During
the off-drug period,
Investigator-
initiated study
funded by Shire
Pharmaceutical
Inc.
Subjects adhered
to MTS only 56% of
the time (range
4-91%), this is not
considered on the
statistical analysis.
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Table 1 (continued )
Author,
year
Study design/
blindness
Diagnostic
criteria/
inicial
sample/n1
dropouts
Randomized
sample/gender/
mean age/driving
experience
Drug/dosage Evaluation/method Main results Funding Comments
driven in the last
year 13,967 (7523)
miles.
measured with
MemsCaps
with drug and
another 3 months in
no-drug condition.
patients were more
likely to have
sudden
decelerations
(po0.001), more
likely to be wearing
seatbelts
(po0.001), less
likely to be smoking
(p=0.014), less
likely to be driving
after dark when
streetlights were
on (0.029), and
more likely to be
driving during bad
weather conditions
(p=0.009). There
were more drives
with passengers
present (po0.001)
and drivers were
more likely to be
interacting with a
passenger
(po0.001).
Open label. Sample
with only
3 females.
Participants
received US
$600,00.
Sobanski
et al.
(2013)
Randomized,
single-blinded,
with a waiting list
control group study
DSM-IV/75
adults
screened/69
included
43 Patients
analyzed/ATX
group (n=22): 13
males and
9 females;
34.778.8 y.o.;
16.479.0 years of
licensed driving;
driving distance per
year:
ATX uptitrated for
4 weeks up to
80 mg/day, then
kept stable for the
next 8 weeks.
On-road driving
assessed with
Standardized
Driving Behavior
Observation
(SDBO). SDBO was
completed while
patients drove on
weekdays for
45 min on a ﬁxed
Mean ATX dosage:
71.6714.9 mg/day.
At baseline, ATX
and control groups
did not differ in
years of licensed
driving, annual
mileage, number
and causes of
trafﬁc accidents,
Eli Lilly
(Investigator
Sponsored Trial).
Patients were not
blind to study
condition (ATX or
waiting list).
12-week interval
between baseline
and second
evaluation.
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28289.5726289.5
(range: 500–
100,000) km/
Control group
(waiting list of
ADHD patients)
(n=21): 9 males
and 12 females;
37.479.5 y.o.;
18.479.1 years of
licensed driving;
driving distance per
year:
15,998718754.2
(range: 960–88,000)
km
route during rush
hour in a city. At 64
predeﬁned
locations, a trafﬁc
psychologist rated
driving
performance in the
categories
“Orientation”,
“Attention”, “Risk-
related self-
control” and
“Driver Skills”.
ﬁnes, driving
license suspension
and revocation.
ATX group
signiﬁcantly
reduced driving
errors in two of
four scores of the
SDBO (after
correction for
baseline
differences):
attention (po0.05;
EF=0.67) and
driver skills
(po0.005;
EF=0.90)
compared to
control group. A
trend towards a
better risk-related
self-control
(po0.10; EF=0.56)
was observed in the
ATX group. Baseline
scores and annual
mileages included
in statistical
analysis as
covariates.
EF= effect size (Cohen’s d unless otherwise stated).
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M.A. Gobbo, M.R. Louzã1438the medication. In the studies that used ATX, the driving
simulation was conducted 3–12 weeks after the medication
was started.
Twelve studies used a placebo-controlled study design.
Four of these studies compared MPH-IR with a placebo (Cox
et al., 2000; Bjørkli et al., 2005; Barkley et al., 2005;
Verster et al., 2008), three studies compared MPH-OROS or
MAS-XR with a placebo (Cox et al., 2006,, 2008; Mikami
et al., 2009), two studies compared ATX with a placebo
(Barkley et al., 2007; Kay et al., 2009), one study compared
MAS-XR with a placebo (Kay et al., 2009), and two studies
compared LDX with a placebo (Biederman et al., 2012a;
Biederman et al., 2012b). One trial compared MPH-OROS
with MPH-IR (Cox et al., 2004b), two studies compared the
drug (MPH-OROS or MTS) to a no-drug condition (Cox et al.,
2004a; Cox et al., 2012, respectively), and one study
compared ATX to a waiting-list control group (Sobanski
et al., 2013).
The sample size included fewer than 20 patients in seven
studies (Cox et al., 2000, 2004a, 2004b; Barkley et al.,
2007; Verster et al., 2008; Kay et al., 2009; Cox et al.,
2012). The other ﬁve studies included 35, 45, 54, 61, and 43
patients (Bjørkli et al., 2005; Barkley et al., 2005; Cox
et al., 2006; Biederman et al., 2012a; Sobanski et al., 2013,
respectively). Two studies (Cox et al., 2008; Mikami et al.,
2009) used the same sample as Cox et al. (2006) and one
study (Biederman et al., 2012b) used the same sample as
Biederman et al. (2012a).
The MPH dosage depended on the delivery method: from
10 to 120 mg/day for MPH-IR, 18 to 144 mg/day for MPH-
OROS, and 10 to 30 mg/day for MTS. The MAS-XR dosage
ranged from 15 to 50 mg/day. The ATX dosage varied by
study: 1.2 mg/kg/day in one study, a mean dosage of
71.6 mg/day in another study, and a dose titration schedule
up to 80 mg/day in a third study. The dosage of LDX ranged
from 30 to 70 mg/day.
Eight studies included both male and female patients,
and four studies included only male patients. In the two
studies that used the same sample as Cox et al. (2006), one
study included both the male and female patients (Mikami
et al., 2009) and the other included only the male patients
(Cox et al., 2008).
Three studies (Cox et al., 2004a, 2004b and Cox et al.,
2006) evaluated teenagers (mean age: 17.2–17.8 years old),
and nine studies evaluated adults (mean age: 20.8–38.3
years old). In the two studies (Cox et al., 2000 and Bjørkli
et al., 2005) that included healthy subjects as controls, the
mean age ranged from 21.8 to 31.0 years old. In one study
(Sobanski et al., 2013) that included ADHD patients who
were on a waiting list for treatment as controls, the mean
age was 37.479.5 years old.
Ten studies used a driving simulator (Cox et al., 2000,
2004b, 2006; Barkley et al., 2005; Bjørkli et al., 2005;
Barkley et al., 2007; Kay et al., 2009; Mikami et al., 2009;
Biederman et al., 2012a; Biederman et al., 2012b), and four
studies were conducted exclusively in cars in different
typical driving situations (Cox et al., 2004a, 2012; Verster
et al., 2008; Sobanski et al., 2013). In one study (Cox et al.,
2008), the evaluations were initially conducted using a
simulator followed by two additional evaluations in a car
and a simulator, respectively. Five different brands simula-
tors were used. Cox, Barkley and Biederman used the samesimulator with the same or slightly different scenarios in
more than one study (Cox et al., 2000, 2004b, 2006, 2008;
Barkley et al., 2005, 2007; Biederman et al.2012a,2012b).
Bjørkli et al. (2005) used a simulator in a single study and
Kay et al. (2009) tested two drugs independently (MAS-XR
and ATX), but the results are presented in a single paper.
Courses and scenarios varied widely. Usually in a simula-
tion different kinds of scenarios, including highway, country
and city driving were included in the same task. Even
though these scenarios may reproduce “boring” or “more
stimulating” conditions (like a monotonous road or a urban
course with different interferences of other cars or pedes-
trians) they usually are not analyzed separately. In most of
the studies the outcomes (driving errors, collisions and so
on) are measured considering the whole simulation. One
exception is the trial by Bjørkli et al. (2005) where he used
5 different scenarios and analyze the results for each
scenario separately. The studies with cars used also differ-
ent courses, from a 16-mile course with rural, highway and
urban driving (Cox et al., 2004a, 2008) to a 100-km highway
during normal trafﬁc (Verster et al., 2008) or a 45-min urban
course in weekdays during rush hour (Sobanski et al., 2013).
Cox et al. (2012) monitored drivers with cameras on the
rearview mirror for 3 months, but do not provide informa-
tion about the distance driven during these 3 months, where
patients drove (urban areas, roads?) and if the different
patients drove in different situations.
Overall, most studies indicated that the use of psychosti-
mulant drugs signiﬁcantly improved driving performance in
patients with ADHD. Two studies (Cox et al., 2000; Verster
et al., 2008) reported that patients who were treated with
MPH-IR had signiﬁcantly better driving performance than
patients (Verster et al., 2008) or non-ADHD controls (Cox
et al., 2006) that were treated with placebo. Barkley et al.
(2005) found that 20 mg of MPH-IR more effectively improved
driving performance compared with10 mg; however the 10 mg
dose of MPH-IR was more effective than placebo only on
number of turn signals, not in other measures.
In one study that included a sample of 35 patients
(19 males and 16 females), MPH-OROS signiﬁcantly
improved driving performance measured at 5:00 PM, 8:00
PM, and 11:00 PM compared with placebo or MAS-XR;
however, driving performance in patients treated with
MAS-XR was not signiﬁcantly different from patients treated
with placebo (Cox et al., 2006). A subsample of these
patients (19 males) was tested again on the road at
midnight using a car and on a driving simulator at 1:00
AM. Patients who were treated with MAS-XR but not MPH-
OROS showed a signiﬁcant decline in their driving perfor-
mance compared with placebo. The authors suggested that
MAS-XR may possibly have a rebound effect, although the
sample size was not large enough to reach a deﬁnite
conclusion (Cox et al., 2008). No gender differences were
observed in a post-hoc analysis that compared the driving
performance of males (n=19) and females (n=16) at 5:00
PM, 8:00 PM and 11:00 PM (Mikami et al., 2009).
Four studies reported no effects of either MPH-IR (Bjørkli
et al., 2005; Verster et al., 2008) or ATX (Barkley et al.,
2007 and Kay et al., 2009) on driving performance compared
with a placebo. However, Sobanski et al. (2013) found that
driving performance in the ATX group was signiﬁcantly
better than the control group.
1439Inﬂuence of treatment on driving in ADHDTwo studies (Cox et al., 2004a, 2012) compared a drug
and no-drug condition instead of using a placebo arm, and
one study used patients on a treatment waiting list as
controls (Sobanski et al., 2013). Patients treated with MPH-
OROS, MTS, or ATX showed better driving performance than
patients in the no-drug or waiting-list arms.
From the studies conducted with simulators, six showed
efﬁcacy of the drug tested (Cox et al., 2000, 2004b, 2006,
Barkley et al., 2005; Kay et al., 2009 for MAS-XR and
Biederman et al., 2012a) and 3 trials were negative
(Bjorkli et al., 2005; Barkley et al., 2007 and Kay et al.,
2009 for ATX). The studies derived from the study of Cox
et al., 2006 (Cox et al., 2008 and Mikami et al., 2009) and
from the study of Biederman et al., 2012a (Biederman
et al., 2012b) were also positive. The ﬁve studies conducted
with cars showed statistically signiﬁcant results, three with
MPH-OROS (Cox et al., 2004b, 2008), one with MPH-IR
(Verster et al., 2008), one with MTS (Cox et al., 2012) and
one with ATX (Sobanski et al., 2013). Nevertheless, in the
study of Cox et al. (2008) MPH-OROS, but not MAS-XR,
improved driving performance of ADHD patients and in the
study of Verster et al. (2008) the statistically signiﬁcant
difference in the standard deviation of lateral position
(SDLP) weaving between placebo and MPH-IR was 2.3 cm
in a car driving at 95 km/h, that could be considered
clinically irrelevant and the SDLP (mean: 21.1 cm with
placebo) can be considered within normal range (Verster
and Roth, 2011).
Six studies were completely funded by a pharmaceutical
company (Cox et al., 2004a, 2006, 2004b, 2012; Kay et al.,
2009; Biederman et al., 2012a), one study was partially
funded by a pharmaceutical company (Barkley et al., 2007),
and one study was an investigator-initiated sponsored trial
(Sobanski et al., 2013). With one exception (Barkley et al.,
2007), all of these industry-sponsored studies reported a
positive result for the drug that the sponsoring company
produced. Of the four studies that were funded by uni-
versities or foundations, three studies reported positive
results of the drug (Cox et al., 2000; Barkley et al., 2005;
and Verster et al., 2008) and one study reported negative
results of the drug (Bjørkli et al., 2005).
Although patients in the drug conditions experienced
some abdominal pain, nausea, urinary difﬁculty, decreased
appetite, tension, jitteriness, anorexia, weight loss, dry
mouth, insomnia, and bruxism, all side effects were
reported as mild and not signiﬁcant (Barkley et al., 2007;
Cox et al., 2006; Kay et al., 2009; Biederman et al., 2012a).
However, only one study systematically collected data on
the adverse effects of the drug (Biederman et al., 2012a).4. Discussion
Both stimulant and non-stimulant drugs are efﬁcacious in
the treatment of ADHD; stimulant drugs produce the largest
effect sizes and are therefore the primary treatment choice
for ADHD (Seixas et al., 2012). However, RCTs that have
evaluated the effect of ADHD drug treatment on driving
performance are relatively scarce. The present review
found that across existing RCTs with ADHD patients, stimu-
lant drugs were found to improve driving performance
compared with placebo or no-drug conditions, whichcorroborates and widens the results of previous reviews
(Barkley and Cox, 2007; Jerome et al., 2006). Since these
two reviews, 8 trials on the efﬁcacy of drug treatment on
driving performance in ADHD were published, adding new
information on this subject, testing new drugs (e.g., LDX)
and extending and strengthening the ﬁndings already
published.
The studies that were included in the present review
showed that patients who were treated with MPH-OROS had
better driving performance than patients in the MAS-XR,
placebo, or no-drug conditions (Cox et al., 2004a and Cox
et al., 2006). MPH-OROS and MPH-IR similarly improved
driving performance during the day. However, MPH-IR lost
its efﬁcacy during the evening, which may increase the risk
of driving problems for patients with ADHD (Cox et al.,
2004b). In one study that used the same sample as Cox et al.
(2006) no gender differences in MPH-OROS efﬁcacy were
found (Mikami et al., 2009). In another study that used the
same sample as Cox et al. (2006), MPH-OROS maintained its
efﬁcacy late at night. However, a rebound effect of MAS-XR
was observed, which may enhance the risk of driving
problems for ADHD patients who are taking this medication
(Cox et al., 2008).
Of the ﬁve studies that evaluated MPH-IR, three studies
reported improvements in performance compared with
placebo or showed similar results compared with MPH-
OROS, even for relatively low doses (Barkley et al., 2005;
Cox et al., 2000, 2004b). These studies used a driving
simulator. Two of these studies tested relatively inexper-
ienced drivers (Cox et al., 2000, 2004b) and one study
tested adult drivers with more years of experience (Barkley
et al., 2005). Among experienced adult drivers, no clear
difference was observed between the 10 and 20 mg doses of
MPH-IR, perhaps because the more experienced drivers
were less likely to make errors. Two studies that used
MPH-IR, however, did not report clear differences between
the MPH-IR and placebo conditions. The ﬁrst study (Bjørkli
et al., 2005) tested experienced drivers in tasks that were
not as complex as real-world driving situations, which may
explain the negative ﬁnding. Although the authors of the
second study (Verster et al., 2008) found a 2.3 cm differ-
ence in weaving on a road between the drug and placebo
conditions, this difference may be considered negligible in a
car that is traveling at 95 km/h. Finally, as previously
described, tests that were conducted late in the evening
revealed that patients in the MPH-IR group showed poorer
driving performance compared with patients in the MPH-
OROS group (Cox et al., 2004b). Therefore, the improve-
ment in driving performance observed with MPH-IR seems to
depend on the conditions under which the study was
performed and the results may not be as consistent as the
results with MPH-OROS. The short duration of action of MPH-
IR may also be related to these results.
One study reported that long-acting MTS treatment led to
a reduction in the number of collisions when patients drove
their own cars (Cox et al., 2012). The results of this study,
however, may have been compromised due to the small
sample size and the large variability in the percentage of
days that patients administered MTS correctly. Further-
more, this study was an open-label study in which patients
receiving treatment were compared with a no-drug condi-
tion rather than a placebo condition.
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(Cox et al., 2006, 2008; Mikami et al., 2009), Kay et al.
(2009) concluded that MAS-XR treatment had better effects
on driving performance than a placebo in a small sample of
ADHD patients. Their results agreed with the results
reported by Cox et al. (2006). However, Kay et al. (2009)
did not test driving performance late in the evening, and
therefore this study was not able to observe a possible
rebound effect.
Two studies on ATX produced negative ﬁndings (Barkley
et al., 2007; Kay et al., 2009), perhaps because both studies
evaluated more experienced adult drivers. In the Kay et al.
(2009) study, the highest dose of ATX that was given was
80 mg/day, which may not be high enough for some
patients. Barkley et al. (2007), however, used a 1.2 mg/
kg/day dose and also observed negative results. Both
studies had small sample sizes and used crossover designs
with no washout between phases. Another study (Sobanski
et al., 2013) showed improvements in driving performance
in patients that used ATX compared with a waiting-list
control group. This study found that the ATX group had a
signiﬁcantly reduced number of driving errors in three of
four scores (attention, risk-related self-control, and driver
skills) on the Standardized Driving Behavior Observation
(SDBO) compared with the waiting-list control group. How-
ever, an important limitation of this study is that the study
was single-blind: patients but not trafﬁc psychologists were
aware of the condition (medication or waiting list) during
the driving test. The authors did not address the inﬂuence
of these conditions on the results of the study. Furthermore,
in both studies that reported negative results (Barkley
et al., 2007; Kay et al., 2009), the driving tests were
conducted 3–4 weeks after taking the medication. This time
frame may have contributed to the negative results because
ATX may take up to 12 weeks to achieve its full efﬁcacy.
The study by Sobanski et al. (2013), which had a bigger
sample size and tested the patients after 12 weeks of
exposure to ATX, reported positive results.
The two studies on the efﬁcacy of LDX, which reported
results from the same sample, concluded that LDX has a
positive effect on driving performance compared with
placebo (Biederman et al., 2012a, 2012b). Although the
sample size was relatively large, no information was given
about the different ADHD subtypes or gender differences
within the sample. The difference between the drug and
placebo conditions may have been enhanced because the
drivers were young and relatively inexperienced and
because the second session of the simulator presented a
difﬁcult driving scenario with ﬁve surprise events.
It is noteworthy that in all trials, with the exception of
Cox et al. (2008) study with MAS-XR where a rebound effect
was observed with worsening of driving performance,
treatment with psychostimulants or ATX in therapeutic
dosages did not had a negative impact on driving perfor-
mance of ADHD patients.
Both studies conducted in simulators and in cars show
differences between experimental and control conditions in
ADHD patients. So, negative results observed in some
studies seem not to be due to a kind of videogame-like
stimulating effect produced by simulators. Studies using
cars are obviously more realistic, but at the same time,
measurements are more difﬁcult to obtain as cameras or anevaluator sitting in the car may inhibit the driver and make
him conduct more cautiously. The evaluation of the efﬁcacy
of the drug does not seem to be inﬂuenced only by the fact
that the study is performed on cars or simulators. Other
variables, such as the kind of courses and scenarios may also
have a more important impact on the results of the trials.
Although the results of our review suggest that stimulants
improve driving performance in ADHD, some methodological
limitations of the RCTs should be considered. The relatively
small number of RCTs prevents us from drawing clear
conclusions. Although we reviewed 15 studies, three of
these studies used the same sample to examine additional
inﬂuences of drug treatments on driving performance.
Therefore, only 12 original studies are included in this
review. Furthermore, most studies employed small sample
sizes (i.e., less than 20 subjects); only ﬁve studies employed
sample sizes larger than 30 subjects. So, effect sizes should
be interpreted with caution as they could be biased due to
the small sample size of most of the trials (Elbourne et al.,
2002; Durlak 2009). Furthermore, most studies included
only male patients or a disproportionally small number of
female patients. Two exceptions are the studies by Mikami
et al. (2009), which speciﬁcally examined gender differ-
ences, and Biederman et al. (2012a, 2012b), which did not
investigate possible gender differences. Although previous
studies have reported that males and females exhibit
different driving styles (Vavrik, 1997; Bina et al., 2006;
Elliott et al., 2006; Classen et al., 2013), it is not currently
known whether males and females with ADHD drive differ-
ently. Therefore, it is difﬁcult to extrapolate ﬁndings from
studies that primarily used male patients to the female
population.
The age and driving experience of the patients may also
inﬂuence the results. Healthy adolescents and young adults
drive more dangerously than older adults (Bina et al., 2006;
Elliott et al., 2006). We observed that RCTs that included
teenagers and young adults with ADHD tended to yield
positive results, whereas studies that included older adults
with ADHD tended to yield negative results. This observa-
tion suggests that less-skilled drivers may derive greater
beneﬁts from psychostimulants than more-skilled drivers.
Furthermore, experienced adult drivers with ADHD may be
more aware of their symptoms and limitations and therefore
may drive more carefully even without medications. Some
studies enforced inclusion criteria such as a minimum
number of years of driving experience or a minimum number
of kilometers driven per year, and therefore did not
evaluate the potential relationship between years of experi-
ence and driving performance. In addition, some studies
excluded patients whose driver’s license had been revoked,
which may have prevented the inclusion of a potentially
more severe ADHD population (Kay et al., 2009; Biederman
et al., 2012a).
ADHD subtypes and the presence of comorbidities were
not considered in most studies. In some studies, patients
with the most severe comorbidities were excluded, whereas
other studies included patients with comorbidities such as
conduct disorder, obsessive-compulsive disorder, and sub-
stance abuse. Furthermore, some studies selected patients
with either combined or inattentive ADHD subtypes. Studies
seldom included hyperactive-impulsive subjects. Therefore,
the inﬂuence of drug treatment on the performance of
1441Inﬂuence of treatment on driving in ADHDthese “more dangerous” drivers could not be evaluated.
This subtype would be, at least theoretically, more prone to
make deliberate violations than unintentional errors hence
increasing the risk of mishaps with more severe conse-
quences (Vaa, 2014).
Three studies used a parallel design (Biederman et al.,
2012a, 2012b; Sobanski et al., 2013) and the remaining
studies employed a balanced crossover design. However,
some of these crossover studies did not include a washout
period between the two phases of the trial. Although the
drugs that were used in these studies have a maximum half-
life of 12–14 h, a possible carryover effect cannot be
excluded. In addition, although most studies were double-
blind, patients who have previously taken stimulants may
have been able to distinguish between the drug and placebo
conditions. Allocation concealment was also not employed
in any of the studies. Furthermore, trials were conducted
relative to drug administration in two different ways.
A driving test was given either approximately 1.5 h after a
single drug treatment or some weeks after a long-term drug
treatment. It is not clear how these two types of study
designs may have inﬂuenced the results. Studies that
examine the acute effect of a single treatment are not as
representative of a real-world situation as studies that
evaluate patients at both baseline and after several weeks
of drug treatment, which can examine the long-term use of
the drug.
In the studies included in the present review, driving
performance was evaluated in either cars or driving simu-
lators. Even sophisticated simulator software and hardware,
however, cannot fully mimic the complex act of driving.
Participants who interacted with driving simulators may
have been aware that no real risk to themselves or others
existed, and therefore these participants may have driven
with less engagement. Furthermore, two studies (Barkley
et al., 2005; Biederman et al., 2012a) that used driving
simulators had to exclude participants who experienced
simulator sickness, which is an adverse event in which
drivers experienced nausea and vertigo in the driving
simulator (Brooks et al., 2010; Classen et al., 2011).
Participants who are required to drive their own cars,
equipped with either cameras or a human observer, may
drive more carefully. Studies in which participants use their
own cars may also allow for lengthier trials (e.g., using
cameras to detect errors or risky situations) that reﬂect
more realistic driving conditions. However, in some studies
(Cox et al., 2004a; Sobanski et al., 2013), the presence of
an observer in the rear seat may promote more careful
driving, which would reduce the ability to detect differ-
ences between control and experimental conditions.
Furthermore, although observers had a standard checklist
of errors to record during the driving tests, a potential
subjective bias may inﬂuence their scores.
Among the studies that employed a driving simulator,
there was a wide variation in the types of simulators and
simulation software. Studies utilized urban driving scenar-
ios, rural driving scenarios, or a combination of urban and
rural situations. The duration of the simulations varied from
12 to 75 min. Shorter durations may not be sufﬁcient to
detect differences between the drug and placebo conditions
because drivers had not yet grown weary of the task.
Studies that have used continuous performance tasks haveshown that inattention- and impulsivity-related errors occur
after a long time on task when subjects eventually lose their
concentration or react impulsively to a stimulus (Huang-
Pollock et al., 2012; Reimer et al., 2007). Because practice
effects may also inﬂuence results, in some studies the
driving scenarios were changed from trial to trial. These
different scenarios should have the same difﬁculty level,
however, to avoid the introduction of a confounding effect
between the experimental and control conditions.
None of the reviewed studies considered the role of
motor coordination in driving performance. Developmental
coordination disorder has been described in children with
ADHD and has been shown to persist into young adulthood
(Rasmussen and Gillberg, 2000). These individuals are
typically unskilled, clumsy, and have difﬁculty with hand-
writing. Because driving demands good motor coordination
(Sobanski et al., 2008), ADHD drivers with poor motor
coordination may exhibit worse driving performance than
ADHD drivers with unaffected motor coordination.
The ﬁnancing of drug trials by the pharmaceutical
companies may inﬂuence the results by favoring the drug
of the manufacturer. In our review, nine of eleven trials that
were partially or completely ﬁnanced by a pharmaceutical
company yielded a positive result for the drug. Even though
this observation alone does not indicate that the trials were
compromised, this fact should be considered in the inter-
pretation of the results. It has to be considered that three
of the four trials that were ﬁnanced by universities or
foundations also reported positive results.
Financial compensation was provided to the participants
in some of the studies, and varied from US$20.00 to
US$600.00. No study, however, estimated the inﬂuence of
this incentive on the motivation of subjects to demonstrate
good driving performance (Festinger et al., 2008; Largent
et al., 2012).
The methodological limitations of the trials are important
factors to be considered when analyzing the results. They
suggest that an ‘ideal’ trial to test the efﬁcacy of drugs on
the driving performance of ADHD patients is yet to be done.
On the other hand, despite this, the fact that most of the
trials show a positive result may speak in favor of the
consistence of the results observed.
RCTs with ADHD patients show that MPH-OROS improves
driving performance compared with MAS-XR, placebo, or no-
drug conditions. Although MPH-OROS and MPH-IR produce
similar improvements in driving performance during the day,
MPH-IR loses its efﬁcacy in the evening. MAS-XR also
improves driving performance, but loses its efﬁcacy and
leads to worse driving performance in the evening. MTS may
have a positive effect on driving, but drug compliance
varied widely across patients. LDX may also have a positive
effect on driving, but so far only two studies with the same
sample are published. Studies of the effect of ATX on driving
performance report conﬂicting results. Across all studies,
the effect of the drug on improvement in driving perfor-
mance was more relevant among teenagers and young
adults.
Adolescents and young adults with ADHD, usually less
experienced drivers are, at the same time, putting them-
selves in risk of negative driving outcomes (e.g., by using
cell phones and texting or by increased risk taking
and behaviors secondary to hyperactivity/impulsivity and
M.A. Gobbo, M.R. Louzã1442distraction) (Graziano et al., 2014; Merkel et al., 2013;
Narad et al., 2013), specially if they have comorbidities
such as Oppositional Deﬁant Disorder or Conduct Disorders
(Vaa, 2014). The investigation of the driving style should be
part of the thorough psychiatric examination of this popula-
tion as the reduction of risky driving is an important priority
of public health. The evidence so far shows that a proper
pharmacological intervention improve ADHD symptoms and
may reduce risky driving behaviors and their negative
consequences.
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